fluconazole 100mg reviews can you buy ventolin inhaler over the counter uk azithromycin buying online farmacia viagra sin receta viagra aangeboden vendo cialis generico
comprare cialis sicuro 
acquisto cialis in italia 
comprar generico de viagra en españa 
bupropion generic vs wellbutrin 100mg clomid iui success stories paxil 5 mg weight gain
achat cialis en martinique vente cialis en suisse cialis hypertension
    viagra aangeboden prix du medicament levitra köpa kamagra billigt

Positive data announced for Reolysin in head and neck cancers

Sun, Dec 23, 2012

Oral Cancer News

Source: www.empr.com
Author: staff

Oncolytics Biotech announced positive top line data in its double-blinded randomized Phase 3 clinical study examining Reolysin in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers. Reolysin is a proprietary formulation of the human reovirus.

A first analysis compared the relative percentages of patients in the test and control arms with tumors that had either stabilized or exhibited shrinkage. For the purposes of this endpoint, the definition of tumor stabilization was restricted to 0% growth only. Of the 105 total patients with evaluable metastatic tumors, 86% (n=50) of those in the test arm of the study exhibited tumor stabilization or shrinkage, compared with 67% of patients (n=55) in the control arm. This was statistically significant, with a p-value of 0.025.

A second analysis examined the magnitude of tumor response on a per patient basis using a comparison of percentage tumor shrinkage at six weeks in each patient with evaluable metastatic tumors. This analysis showed that Reolysin in combination with carboplatin and paclitaxel was statistically significantly better than carboplatin and paclitaxel alone at stabilizing or shrinking metastatic tumors, yielding a p-value of 0.03

Print Friendly
Be Sociable, Share!
, , , , , ,

Leave a Reply

You must be logged in to post a comment.